Peptide Initiative

Peptides · Peptide comparison

Cartalax vs Ovagen

Chondroprotective tripeptide bioregulator (Ala-Glu-Asp) that activates chondrogenic differentiation through SOX9/COL2A1/aggrecan upregulation, reverses senescence-associated secretory phenotype in aging chondrocytes, and provides geroprotective effects through SIRT-6 upregulation and p16/p21/p53 suppression

Hepatoprotective tripeptide bioregulator (Glu-Asp-Leu) that penetrates hepatocyte nuclei to bind DNA in the minor groove at AT-rich promoter regions, upregulates antioxidant enzymes (SOD, glutathione peroxidase, GST) beyond melatonin's capacity, and supports liver regeneration through epigenetic activation of hepatocyte proliferation and anti-fibrotic gene programs

  • Anti-Aging
  • Anti-Aging

At a glance

Quick comparison

Dose rangeCartalax200–200 mcgOvagen10–10 mg
FrequencyCartalaxOnce dailyOvagenMultiple times daily
AdministrationCartalaxOral (capsule)OvagenOral (capsule — standard formulation)
Cycle lengthCartalax12+ weeksOvagen8-12 weeks
Onset speedCartalaxGradual (3-4 weeks)OvagenGradual (3-4 weeks)
Evidence levelCartalaxModerate human trials (Phase 1-2)OvagenLimited human trials

Efficacy

Benefit ratings

Anti-Aging

Cartalax8%
Ovagen8%

Healing & Recovery

Cartalax8%
Ovagen8%

Hormone Support

Cartalax6%
OvagenNo recorded rating

Metabolic

CartalaxNo recorded rating
Ovagen7%

Technical data

Compound specifications

Cartalax

Molecular formula
C12H19N3O8
Molecular weight
333.3 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids
Bioavailability
Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)
CAS number
Not yet registered (research compound)

Ovagen

Molecular formula
C15H25N3O8
Molecular weight
375.4 g/mol
Half-life
Short plasma half-life typical of tripeptides; biological effects persist for weeks through epigenetic modifications to hepatic gene expression; metabolized to constituent amino acids (glutamic acid, aspartic acid, leucine)
Bioavailability
Effective via oral capsule (10 mg twice daily), sublingual liquid (0.1 mg/mL), and subcutaneous injection routes; penetrates cell membranes and nuclear membranes as a cell-penetrating peptide; tissue-specific activity demonstrated in organotypic hepatic cultures at 10⁻⁶ to 10⁻⁹ M
CAS number
Not assigned (proprietary Khavinson peptide)

Protocols

Dosing compared

Cartalax

Subcutaneous

  • 200 mcgOnce daily · 10-day cycles, repeated periodicallyCartalax has only lab and cell-culture research, so there is no trial-set human dose. In practice it is commonly given as 200 mcg daily in short 10-day cycles, matching how other Khavinson short peptides are used [3][4].

Ovagen

Oral

  • 10 mg (1 capsule) twice dailyTwice daily with meals · 10-20 day course, repeatable after 3-6 monthsDocumented bioregulator practice dose for the EDL liver/GI peptide [2]. No controlled human trials; data are preclinical and cell-based.

Applications

Best suited for

Cartalax

Cartilage regeneration and protection in age-related osteoarthritis
Cartalax is particularly well-suited for individuals focused on cartilage regeneration and protection in age-related osteoarthritis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Connective tissue repair and maintenance in aging individuals
Cartalax is particularly well-suited for individuals focused on connective tissue repair and maintenance in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
Cartalax is particularly well-suited for individuals focused on geroprotective therapy targeting the sirt-6/senescence axis in musculoskeletal tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy
Cartalax is particularly well-suited for individuals focused on complementing conventional osteoarthritis treatments with bioregulatory peptide therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Ovagen

Supporting liver function and hepatoprotection in aging individuals
Ovagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting hepatic aging and metabolic health
Ovagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting hepatic aging and metabolic health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery support after hepatic injury or liver disease
Ovagen is particularly well-suited for individuals focused on recovery support after hepatic injury or liver disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for maintaining liver regenerative capacity during aging
Ovagen is particularly well-suited for individuals focused on geroprotective therapy for maintaining liver regenerative capacity during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Cartalax

Common

  • Mild injection site reaction
  • Mild GI discomfort
  • Mild fatigue
  • Transient joint stiffness

Uncommon

  • Temporary increase in joint discomfort

Serious

  • No documented serious adverse effects

Ovagen

Common

  • Mild digestive discomfort
  • Mild fatigue
  • Mild headache
  • Minor appetite changes

Uncommon

  • Mild nausea

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Cartalax

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active joint infection — treat infection before initiating peptide bioregulator therapy
  • Malignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated

Ovagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Ovagen demonstrates favorable safety in reproductive endocrinology applications with no serious adverse events reported in clinical ovulation induction studies. As a kisspeptin analog, primary safety consideration is ovarian hyperstimulation syndrome (OHSS) risk, requiring careful hormone monitoring and patient education on abdominal pain, bloating, and nausea symptoms. Mild headaches and injection site reactions occur in <10% of users. Reproductive safety in animal models shows normal fetal development with no teratogenicity.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, leucine)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Severe glutamic acid metabolism disorders (extremely rare)
  • Active autoimmune hepatitis in flare without physician supervision

Decision guide

Which is right for you?

Cartalax

Choose Cartalax if…

  • Cartilage regeneration and protection in age-related osteoarthritis
  • Connective tissue repair and maintenance in aging individuals
  • Geroprotective therapy targeting the SIRT-6/senescence axis in musculoskeletal tissue
  • Complementing conventional osteoarthritis treatments with bioregulatory peptide therapy

Ovagen

Choose Ovagen if…

  • Supporting liver function and hepatoprotection in aging individuals
  • Comprehensive Khavinson bioregulator protocols targeting hepatic aging and metabolic health
  • Recovery support after hepatic injury or liver disease
  • Geroprotective therapy for maintaining liver regenerative capacity during aging